Stock listing

NASDAQ:RLMD Relmada Therapeutics, Inc. Stock

Home listing (NASDAQ) of Relmada Therapeutics, Inc.

Follow Relmada Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:RLMD

$2.62 USD -0.23 (-8.2%)

Close on Nov 20, 2026

Past year -39.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$2.60 – $3.13 USDNov 20, 2026
Volume
2.25M sharesNov 20, 2026
Market cap
$279.5M USDAt the close on Nov 20, 2026 · price × 106.7M shares outstanding
52-week range
$2.60 – $8.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$5.41M USDMedian day 1.31M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Relmada Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:RLMD · Home$2.62 USD-0.235 (-8.2%)2,249,760$3.07$3.13$2.603$2.855Close on Nov 20, 2026
Frankfurt:4E2€2.68 EUR+0.14 (+5.5%)—€2.68€2.68€2.68€2.54Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RLMD · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$2.62-0.235-8.2%$3.07$3.13$2.6032,249,760
$2.855-0.155-5.1%$2.96$3.091$2.851,860,810
$3.01-0.60-16.6%$3.55$3.60$2.982,089,497
$3.61-0.60-14.3%$4.11$4.14$3.4552,418,931
$4.21+0.05+1.2%$4.70$4.71$3.8151,736,265
$4.16-0.27-6.1%$4.40$4.47$4.1351,038,496
$4.43+0.16+3.7%$4.26$4.525$4.211,504,388
$4.27+0.13+3.1%$4.11$4.31$4.11985,677
$4.14+0.24+6.2%$3.98$4.185$3.91958,590
$3.90+0.13+3.4%$3.81$3.97$3.691,055,409
$3.77-0.40-9.6%$4.325$4.325$3.6851,486,558
$4.17-0.10-2.3%$4.34$4.60$4.112,635,234
$4.27+0.43+11.2%$3.88$4.31$3.882,663,624
$3.84+0.26+7.3%$3.61$3.93$3.5952,256,995
$3.58+0.14+4.1%$3.42$3.655$3.301,413,751
$3.44+0.09+2.7%$3.38$3.485$3.291,609,780
$3.35+0.14+4.4%$3.21$3.36$3.181,614,697
$3.21-0.02-0.6%$3.22$3.33$3.1751,673,657
$3.23-0.04-1.2%$3.30$3.305$3.215775,829
$3.27-0.02-0.6%$3.26$3.335$3.181,100,741
$3.29+0.08+2.5%$3.27$3.41$3.156,281,293
$3.21-0.15-4.5%$3.35$3.395$3.191,720,536
$3.36+0.20+6.3%$3.17$3.395$3.16740,282
$3.16+0.06+1.9%$3.11$3.21$3.075746,309
$3.10-0.10-3.1%$3.21$3.29$3.071,279,415
$3.20-0.04-1.2%$3.27$3.35$3.185909,041
$3.24-0.12-3.6%$3.31$3.37$3.1951,354,317
$3.36-0.15-4.3%$3.50$3.55$3.3551,424,367
$3.51+0.12+3.5%$3.39$3.535$3.3151,423,670
$3.39+0.22+6.9%$3.18$3.535$3.1551,730,502
$3.17-0.08-2.5%$3.23$3.32$3.101,886,414
$3.25-0.03-0.9%$3.26$3.355$3.241,497,317
$3.28-0.20-5.7%$3.50$3.50$3.2651,735,689
$3.48-0.12-3.3%$3.60$3.70$3.4151,282,546
$3.60-0.06-1.6%$3.72$3.73$3.601,209,548
$3.66-0.11-2.9%$3.73$3.80$3.651,358,477
$3.77+0.04+1.1%$3.78$3.845$3.72999,525
$3.73-0.06-1.6%$3.82$3.89$3.695863,545
$3.79-0.04-1.0%$3.80$3.855$3.71986,628
$3.83+0.02+0.5%$3.81$3.87$3.731,311,049
$3.81+0.03+0.8%$3.74$3.875$3.661,325,332
$3.78-0.46-10.8%$4.26$4.26$3.771,130,083
$4.24+0.08+1.9%$4.16$4.27$4.145662,654
$4.16+0.04+1.0%$4.13$4.235$4.075552,734
$4.12-0.08-1.9%$4.15$4.17$4.062,069,829
$4.20-0.02-0.5%$4.28$4.39$4.18772,911
$4.22-0.22-5.0%$4.45$4.572$4.205824,376
$4.440.000.0%$4.44$4.495$4.301,998,635
$4.44-0.08-1.8%$4.52$4.56$4.421,264,731
$4.52+0.45+11.1%$4.60$4.65$4.2952,629,279
$4.07-0.02-0.5%$4.25$4.25$4.002,808,981
$4.09-0.16-3.8%$4.24$4.28$4.091,590,041
$4.25-0.18-4.1%$4.40$4.425$4.131,697,806
$4.43+0.06+1.4%$4.35$4.44$4.32675,555
$4.37-0.17-3.7%$4.55$4.58$4.33847,511
$4.54+0.08+1.8%$4.54$4.593$4.3651,416,552
$4.46+0.10+2.3%$4.31$4.51$4.31944,057
$4.36+0.03+0.7%$4.31$4.395$4.285628,242
$4.33-0.19-4.2%$4.51$4.53$4.32678,358
$4.52-0.03-0.7%$4.53$4.58$4.485496,494
$4.55-0.04-0.9%$4.57$4.60$4.46476,693
$4.59+0.01+0.2%$4.63$4.725$4.571,025,383
$4.58-0.05-1.1%$4.64$4.64$4.375935,748
$4.63-0.01-0.2%$4.68$4.76$4.54985,172
$4.64-0.19-3.9%$4.74$4.79$4.551,033,935

Splits

2 splits since 2015 · NASDAQ:RLMD · every price before a split is adjusted for it

DayRatioWhat
1-for-4Consolidation
1-for-5Consolidation
Ticker
NASDAQ:RLMD
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Relmada Therapeutics, Inc. news

Relmada Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
21 in the last 12 months · 111 in all · newest Nov 16, 2026 · oldest 2019
Calls
24 calls with a replay · 24 with a transcript · latest Nov 12, 2026
Decks
35 decks · latest Nov 12, 2026

Where Relmada Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:RLMD · Home listing · This pageNASDAQUnited StatesUSD
gettex:4E2gettexGermanyEUR
LS Exchange:A2PSZFLS ExchangeGermanyEUR
Lang & Schwarz:A2PSZFLang & SchwarzGermanyEUR
BOATS:RLMDBOATSUnited StatesUSD
Frankfurt:4E2FrankfurtGermanyEUR
Tradegate:4E2TradegateGermanyEUR
Dusseldorf:4E2DusseldorfGermanyEUR
Hamburg:4E2HamburgGermanyEUR
Munich:4E2MunichGermanyEUR
Stuttgart:4E2StuttgartGermanyEUR

Valuation

Price/book 1.4× against a median of 3.3×: 3rd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$77.42M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
1.4×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.57

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Relmada Therapeutics, Inc. · NASDAQ:RLMDUS$279.5MUS$77.42Mn/an/an/a1.4×n/a0.0×1.57
Contineum Therapeutics, Inc. · NASDAQ:CTNMUS$286.1MUS$47.86Mn/an/an/a1.2×n/a0.0×1.53
TRex Bio, Inc. · NASDAQ:TRXBUS$283.1MUS$205.0Mn/an/an/an/an/an/an/a
Greenwich LifeSciences, Inc. · NASDAQ:GLSIUS$282.6MUS$276.7Mn/an/an/an/an/an/a2.80
Precision BioSciences, Inc. · NASDAQ:DTILUS$282.5MUS$228.3Mn/a5.1×n/a5.5×−85.6%0.5×0.30
AP Biosciences, Inc. · TPEX:6945US$282.2MUS$215.6Mn/an/an/a4.0×n/a0.0×n/a
Fulcrum Therapeutics, Inc. · NASDAQ:FULCUS$281.8M−US$17.87Mn/an/an/a0.9×n/a0.0×0.42
Circio Holding ASA · OSL:CRNAUS$281.1MUS$225.9Mn/an/an/a5.3×n/a0.0×n/a
Benitec Biopharma Inc. · NASDAQ:BNTCUS$276.1MUS$99.78Mn/an/an/a1.6×n/a0.0×1.46
Vicore Pharma Holding AB · OMXSTO:VICOUS$271.4MUS$182.7Mn/a467×n/a3.3×n/a0.0×n/a
Galectin Therapeutics Inc. · NASDAQ:GALTUS$271.4MUS$293.0Mn/an/an/an/an/an/a1.20
Median of the othersUS$282.0MUS$210.3M236×3.3×−85.6%0.0×1.33

Forecasts

3 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
10.75 USD · Analysts' mean
EPS, year to Dec 2026
-0.41 · 1 analyst

Team and board

Officers

OfficerRole
Sergio TraversaChief Executive Officer
Maged ShenoudaChief Financial Officer
Paul KellyChief Operating Officer
Bipin DalmiaChief Business Officer
Chuck EnceChief Accounting and Compliance Officer
Jørn Skibsted JakobsenChief Development Officer, Urology & Uro-Oncology

Board

DirectorRole
Charles J. CasamentoChairman of the Board
Fabiana FedeliDirector
John GlasspoolDirector

Events

Calls

CallWhenStatus
Relmada Therapeutics (NASDAQ:RLMD) Q3 2026 Earnings CallThu, Nov 12, 2026 · 4:30 PM ETReplay
Relmada Therapeutics (NASDAQ:RLMD) Q2 2026 Earnings CallThu, Aug 06, 2026 · 4:30 PM ETReplay
Relmada Therapeutics (NASDAQ:RLMD) Q1 2026 Earnings CallTue, May 12, 2026 · 4:30 PM ETReplay
Relmada Therapeutics (NASDAQ:RLMD) Q4 2025 Earnings CallThu, Mar 19, 2026 · 4:30 PM ETReplay
Relmada Therapeutics (NASDAQ:RLMD) Q3 2025 Earnings CallThu, Nov 13, 2025 · 4:30 PM ETReplay
Relmada Therapeutics (NASDAQ:RLMD) Q2 2025 Earnings CallThu, Aug 07, 2025 · 4:30 PM ETReplay
Relmada Therapeutics (NASDAQ:RLMD) Q1 2025 Earnings CallMon, May 12, 2025 · 4:30 PM ETReplay
Relmada Therapeutics (NASDAQ:RLMD) Q4 2024 Earnings CallThu, Mar 27, 2025 · 4:30 PM ETReplay
Relmada Therapeutics (NASDAQ:RLMD) Q3 2024 Earnings CallThu, Nov 07, 2024 · 4:30 PM ETReplay
Relmada Therapeutics (NASDAQ:RLMD) Q2 2024 Earnings CallWed, Aug 07, 2024 · 4:30 PM ETReplay
All 24 calls
CallWhenStatus
Relmada Therapeutics (NASDAQ:RLMD) Q1 2024 Earnings CallWed, May 08, 2024 · 4:30 PM ETReplay
Relmada Therapeutics (NASDAQ:RLMD) Q4 2023 Earnings CallTue, Mar 19, 2024 · 4:30 PM ETReplay
Relmada Therapeutics (NASDAQ:RLMD) Q3 2023 Earnings CallWed, Nov 08, 2023 · 4:30 PM ETReplay
Relmada Therapeutics (NASDAQ:RLMD) Q2 2023 Earnings CallTue, Aug 08, 2023 · 4:30 PM ETReplay
Relmada Therapeutics (NASDAQ:RLMD) Q1 2023 Earnings CallThu, May 11, 2023 · 4:30 PM ETReplay
Relmada Therapeutics (NASDAQ:RLMD) Q4 2022 Earnings CallThu, Mar 23, 2023 · 4:30 PM ETReplay
Relmada Therapeutics (NASDAQ:RLMD) Q3 2022 Earnings CallThu, Nov 10, 2022 · 4:30 PM ETReplay
Relmada Therapeutics (NASDAQ:RLMD) Q2 2022 Earnings CallThu, Aug 11, 2022 · 4:30 PM ETReplay
Relmada Therapeutics (NASDAQ:RLMD) Q1 2022 Earnings CallThu, May 05, 2022 · 4:30 PM ETReplay
Relmada Therapeutics (NASDAQ:RLMD) Q4 2021 Earnings CallWed, Mar 23, 2022 · 4:30 PM ETReplay
Relmada Therapeutics (NASDAQ:RLMD) Q3 2021 Earnings CallThu, Nov 11, 2021 · 4:30 PM ETReplay
Relmada Therapeutics (NASDAQ:RLMD) Q2 2021 Earnings CallTue, Aug 10, 2021 · 4:30 PM ETReplay
Relmada Therapeutics (NASDAQ:RLMD) Q1 2021 Earnings CallWed, May 12, 2021 · 4:30 PM ETReplay
Relmada Therapeutics (NASDAQ:RLMD) Q4 2020 Earnings CallTue, Mar 23, 2021 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 12, 2026 · After close+1.2%
Q2 2026Aug 6, 2026 · After close−8.0%
Q1 2026May 13, 2026−0.4%
Q4 2025Mar 19, 2026 · After close−2.9%
Q3 2025Nov 13, 2025 · After close+1.8%
Q2 2025Aug 7, 2025−1.9%
Q1 2025May 12, 2025 · After close−2.1%
Q4 2024Mar 17, 2025 · After close+0.4%
Q3 2024Nov 7, 2024 · After close+0.6%
Q2 2024Aug 7, 2024 · After close−29.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 8, 2024 · After close−0.8%
Q4 2023Mar 19, 2024 · After close−17.4%
Q3 2023Nov 8, 2023 · After close−0.3%
Q2 2023Aug 8, 2023 · After close+7.1%
Q1 2023May 11, 2023 · After close−6.3%
Q4 2022Mar 23, 2023 · After close−2.2%
Q3 2022Nov 10, 2022 · After close+8.7%
Q2 2022Aug 11, 2022 · After close+4.6%
Q1 2022May 5, 2022 · After close−5.2%
Q4 2021Mar 23, 2022 · After close+7.6%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck31 slidesNov 12, 2026
Investor Presentation (August 2026)Investor deck32 slidesAugust 2026
Investor Presentation (May 2026)Investor deck40 slidesMay 12, 2026
Investor Presentation (March 2026)Investor deck40 slidesMar 20, 2026
Technical Presentation (March 2026)Technical12 slidesMar 9, 2026
Investor Presentation (November 2025)Investor deck39 slidesNov 13, 2025
Investor Presentation (November 2025)Investor deck39 slidesNov 4, 2025
Investor Presentation (September 2025)Investor deck32 slidesSep 17, 2025
Investor Presentation (August 2025)Investor deck36 slidesAug 7, 2025
Investor Presentation (October 2023)Investor deck36 slidesOct 4, 2023
All 35 decks
DeckKindSlidesDate
Investor Presentation (August 2023)Investor deck34 slidesAug 10, 2023
Investor Presentation (April 2023)Investor deck33 slidesApr 19, 2023
Investor Presentation (January 2023)Investor deck35 slidesJan 9, 2023
Technical Presentation (December 2022)Technical13 slidesDec 7, 2022
Investor Presentation (November 2022)Investor deck23 slidesNov 14, 2022
Investor Presentation (May 2022)Investor deck34 slidesMay 5, 2022
Investor Presentation (March 2022)Investor deck34 slidesMar 7, 2022
Investor Presentation (February 2022)Investor deck30 slidesFeb 23, 2022
Technical Presentation (February 2022)Technical9 slidesFeb 23, 2022
Investor Presentation (December 2021)Investor deck26 slidesDec 20, 2021
Investor Presentation (November 2021)Investor deck26 slidesNov 23, 2021
Investor Presentation (November 2021)Investor deck25 slidesNov 15, 2021
Investor Presentation (October 2021)Investor deck22 slidesOct 7, 2021
Investor Presentation (January 2021)Investor deck30 slidesJan 7, 2021
Investor Presentation (December 2020)Investor deck30 slidesDec 14, 2020
Investor Presentation (November 2020)Investor deck31 slidesNov 16, 2020
Investor Presentation (June 2020)Investor deck28 slidesJun 3, 2020
Investor Presentation (December 2019)Investor deck26 slidesDec 3, 2019
Technical Presentation (October 2019)Technical8 slidesOct 21, 2019
Investor Presentation (April 2018)Investor deck32 slidesApr 5, 2018
Investor Presentation (January 2016)Investor deck35 slidesJan 13, 2016
Investor Presentation (September 2015)Investor deck33 slidesSep 23, 2015
Investor Presentation (May 2015)Investor deck28 slidesMay 22, 2015
Investor Presentation (April 2015)Investor deck28 slidesApr 23, 2015
Investor Presentation (September 2014)Investor deck25 slidesSep 11, 2014

Open Decks

Financings

RaiseDate
Public offering of common stock and pre-funded warrants
Announced: about US$100M · US$2.2 a share · Jefferies +2
Dealers: Jefferies (co-lead), Leerink Partners (co-lead), Mizuho
Buyers: Janus Henderson Investors; Ferring Ventures SA; Squadron Capital Management; Marshall Wace; Spruce Street Capital; OrbiMed; Columbia Threadneedle Investments; Driehaus Capital Management
Use of proceeds: Working capital and general corporate purposes, including clinical studies and further development of product candidates
Nov 4, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2019FY2018FY2018
Revenue0000000
Cost of revenue1.26K3.75K4.87K2.63K
Gross profit-1.26K-3.75K-4.87K-2.63K
Research and development26.9M46.2M54.8M113.3M90.6M36.0M7.86M7.02M2.94M2.94M
Selling, general and administrative311.9K37.7M48.9M47.9M35.1M24.9M7.25M3.98M
Operating income-59.1M-83.9M-103.7M-161.2M-125.7M-60.8M-15.1M-12.7M-6.92M-6.92M
Depreciation and amortization83.9M103.7M2.00K1.26K3.75K4.36K4.87K2.63K2.63K
EBITDA-36-293-161.2M-125.7M-60.8M-15.1M-12.7M-6.91M-6.91M
Interest expense4.21M48.3K1.40M1.34M
Income before tax-57.4M-80.0M-98.8M-157.0M-125.8M-59.5M-15.0M-8.96M
Income tax-103.7K-2.66M48.3K-1.38M4.59M2.05M
Net income-57.4M-80.0M-98.8M-157.0M-125.8M-59.5M-15.0M-17.3M-8.96M-8.96M
Earnings per share, basic-1.45-2.65-3.28-5.30-7.16-3.81-1.62-2.74-2.86-2.86
Earnings per share, diluted-1.45-2.65-3.28-5.30-7.16-3.81-1.62-2.74-2.86

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2019FY2018FY2018
Cash and equivalents3.50M3.86M4.09M5.40M44.4M2.50M36.3M9.22M2.24M2.24M
Short-term investments89.5M41.1M92.2M142.9M167.5M114.6M80.2M
Receivables512.4K86.4K79.5K73.1K72.1K
Inventory4.04M11.3M903.2K459.0K426.9K
Current assets94.0M45.8M97.5M152.9M223.3M118.1M116.9M9.98M2.74M2.74M
Property, plant and equipment1.26K5.01K7.21K7.21K12.1K
Total assets94.0M45.8M97.6M152.9M223.3M118.2M117.1M10.2M3.05M3.05M
Accounts payable1.57M4.13M3.51M5.26M11.2M8.35M522.7K924.4K765.4K765.4K
Current liabilities6.43M10.3M12.2M12.5M15.1M12.6M1.46M2.61M5.90M5.90M
Total debt110.2K2.94M
Total liabilities7.49M10.3M12.2M12.5M15.1M12.6M1.46M2.61M8.56M8.56M
Shareholders' equity86.5M35.5M85.4M140.4M208.3M105.6M115.7M7.61M-5.51M-5.51M
Shares outstanding73.3M30.2M30.1M30.1M27.7M16.3M14.5M9.74M3.14M3.14M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2019FY2018FY2018
Cash from operations-45.8M-51.8M-51.7M-103.8M-91.9M-27.8M-12.1M-10.5M-6.00M-6.00M
Capital spending00-4-3-5-182.1M-84.8M-12.4K-12.4K
Free cash flow-45.8M-51.8M-51.7M-103.8M-91.9M-209.9M-96.9M-6.01M-6.01M
Cash from investing-48.1M51.6M50.5M19.7M-54.1M-34.4M-80.2M-12.4K-12.4K
Cash from financing93.6M-40.3K-98.5K45.0M187.9M28.5M126.1M17.5M6.54M6.54M
Share buybacks42.7M113.9M17.8M
Change in cash-360.5K-234.5K-1.30M-39.0M41.9M-33.8M33.9M6.98M528.4K528.4K

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
8-K · Current reportNov 16, 2026Current reportSEC
8-K · Current reportNov 12, 2026ResultsSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
4 · Change in ownershipSep 11, 2026Insider tradeSEC
4 · Change in ownershipSep 11, 2026Insider tradeSEC
8-K · Current reportSep 8, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
8-K · Current reportAug 6, 2026ResultsSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
Show 200 filings
FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeJul 29, 2026Big-stake noticeSEC
8-K · Current reportJul 28, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeJun 22, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansJun 18, 2026Offer documentSEC
SCHEDULE 13G · Big-stake noticeJun 9, 2026Big-stake noticeSEC
8-K · Current reportMay 28, 2026Meeting outcomeSEC
S-3ASR · Registration statementMay 13, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 13, 2026Big-stake noticeSEC
8-K · Current reportMay 12, 2026ResultsSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeMay 4, 2026Big-stake noticeSEC
DEFA14A · Additional proxy materialApr 17, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 17, 2026Meeting noticeSEC
EFFECT · Notice that a registration is effectiveApr 10, 2026Other filingsSEC
424B3 · ProspectusApr 9, 2026Offer documentSEC
CORRESP · Letter to the SECApr 7, 2026Other filingsSEC
UPLOAD · Letter from the SECApr 7, 2026Other filingsSEC
PRE 14A · Preliminary proxy statementApr 6, 2026Meeting noticeSEC
S-3 · Registration statementApr 3, 2026Offer documentSEC
8-K · Current reportMar 20, 2026ResultsSEC
10-K · Annual reportMar 19, 2026Annual reportSEC
8-K · Current reportMar 9, 2026Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 12, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 6, 2026Big-stake noticeSEC
424B5 · ProspectusJan 30, 2026Offer documentSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
8-K · Current reportDec 15, 2025Management or board changeSEC
SCHEDULE 13G · Big-stake noticeNov 14, 2025Big-stake noticeSEC
8-K · Current reportNov 13, 2025ResultsSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
4 · Change in ownershipNov 6, 2025Insider tradeSEC
4 · Change in ownershipNov 6, 2025Insider tradeSEC
4 · Change in ownershipNov 6, 2025Insider tradeSEC
4 · Change in ownershipNov 6, 2025Insider tradeSEC
8-K · Current reportNov 4, 2025Material contractSEC
424B5 · ProspectusNov 4, 2025Offer documentSEC
FWP · Free writing prospectusNov 4, 2025Offer documentSEC
8-K · Current reportNov 4, 2025Current reportSEC
8-K · Current reportSep 17, 2025Current reportSEC
8-K · Current reportSep 16, 2025Current reportSEC
8-K · Current reportSep 10, 2025Current reportSEC
8-K · Current reportSep 2, 2025Current reportSEC
4 · Change in ownershipAug 28, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
8-K · Current reportAug 7, 2025ResultsSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportJul 23, 2025Current reportSEC
8-K · Current reportJul 10, 2025Current reportSEC
4 · Change in ownershipJun 30, 2025Insider tradeSEC
4 · Change in ownershipJun 30, 2025Insider tradeSEC
4 · Change in ownershipJun 30, 2025Insider tradeSEC
4 · Change in ownershipJun 30, 2025Insider tradeSEC
4 · Change in ownershipJun 30, 2025Insider tradeSEC
4 · Change in ownershipJun 30, 2025Insider tradeSEC
4 · Change in ownershipJun 30, 2025Insider tradeSEC
8-K · Current reportJun 17, 2025Current reportSEC
S-8 · Registration statement for employee plansJun 12, 2025Offer documentSEC
8-K · Current reportMay 27, 2025Meeting outcomeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
10-Q · Quarterly reportMay 12, 2025Quarterly reportSEC
8-K · Current reportMay 12, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeMay 1, 2025Big-stake noticeSEC
424B5 · ProspectusApr 28, 2025Offer documentSEC
8-K · Current reportApr 28, 2025Current reportSEC
DEFA14A · Additional proxy materialApr 11, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 11, 2025Meeting noticeSEC
8-K · Current reportMar 27, 2025ResultsSEC
10-K · Annual reportMar 27, 2025Annual reportSEC
8-K · Current reportMar 26, 2025Material contractSEC
8-K · Current reportFeb 6, 2025Material contractSEC
8-K · Current reportJan 27, 2025Current reportSEC
8-K · Current reportJan 6, 2025Management or board changeSEC
8-K · Current reportDec 9, 2024Current reportSEC
8-K · Current reportDec 4, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
4 · Change in ownershipOct 23, 2024Insider tradeSEC
EFFECT · Notice that a registration is effectiveSep 13, 2024Other filingsSEC
4 · Change in ownershipSep 11, 2024Insider tradeSEC
4 · Change in ownershipSep 11, 2024Insider tradeSEC
4 · Change in ownershipSep 11, 2024Insider tradeSEC
4 · Change in ownershipSep 11, 2024Insider tradeSEC
CORRESP · Letter to the SECSep 11, 2024Other filingsSEC
UPLOAD · Letter from the SECSep 6, 2024Other filingsSEC
S-3 · Registration statementAug 30, 2024Offer documentSEC
10-Q · Quarterly reportAug 7, 2024Quarterly reportSEC
8-K · Current reportMay 30, 2024Meeting outcomeSEC
4 · Change in ownershipMay 29, 2024Insider tradeSEC
4 · Change in ownershipMay 29, 2024Insider tradeSEC
4 · Change in ownershipMay 29, 2024Insider tradeSEC
4 · Change in ownershipMay 29, 2024Insider tradeSEC
4 · Change in ownershipMay 29, 2024Insider tradeSEC
4 · Change in ownershipMay 29, 2024Insider tradeSEC
4 · Change in ownershipMay 29, 2024Insider tradeSEC
10-Q · Quarterly reportMay 8, 2024Quarterly reportSEC
DEFA14A · Additional proxy materialApr 9, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 9, 2024Meeting noticeSEC
8-K · Current reportMar 19, 2024ResultsSEC
10-K · Annual reportMar 19, 2024Annual reportSEC
SC 13G/A · Big-stake notice, amendedMar 6, 2024Big-stake noticeSEC
144 · Notice of proposed saleFeb 20, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
4 · Change in ownershipJan 31, 2024Insider tradeSEC
4 · Change in ownershipJan 31, 2024Insider tradeSEC
4 · Change in ownershipJan 31, 2024Insider tradeSEC
8-K · Current reportJan 11, 2024Management or board changeSEC
8-K · Current reportJan 4, 2024Current reportSEC
8-K · Current reportJan 3, 2024Management or board changeSEC
4 · Change in ownershipDec 19, 2023Insider tradeSEC
4 · Change in ownershipDec 19, 2023Insider tradeSEC
4 · Change in ownershipDec 19, 2023Insider tradeSEC
4 · Change in ownershipDec 19, 2023Insider tradeSEC
4 · Change in ownershipDec 19, 2023Insider tradeSEC
4 · Change in ownershipDec 19, 2023Insider tradeSEC
4 · Change in ownershipDec 19, 2023Insider tradeSEC
10-Q · Quarterly reportNov 8, 2023Quarterly reportSEC
8-K · Current reportNov 8, 2023ResultsSEC
8-K · Current reportOct 11, 2023Current reportSEC
8-K · Current reportOct 10, 2023Current reportSEC
8-K · Current reportOct 4, 2023Current reportSEC
8-K · Current reportSep 20, 2023Current reportSEC
8-K · Current reportSep 6, 2023Management or board changeSEC
8-K · Current reportAug 10, 2023Current reportSEC
8-K · Current reportAug 8, 2023ResultsSEC
10-Q · Quarterly reportAug 8, 2023Quarterly reportSEC
SC 13G/A · Big-stake notice, amendedJul 7, 2023Big-stake noticeSEC
S-8 · Registration statement for employee plansJun 21, 2023Offer documentSEC
4 · Change in ownershipMay 30, 2023Insider tradeSEC
4 · Change in ownershipMay 30, 2023Insider tradeSEC
4 · Change in ownershipMay 30, 2023Insider tradeSEC
4 · Change in ownershipMay 30, 2023Insider tradeSEC
4 · Change in ownershipMay 30, 2023Insider tradeSEC
4 · Change in ownershipMay 30, 2023Insider tradeSEC
4 · Change in ownershipMay 30, 2023Insider tradeSEC
4 · Change in ownershipMay 30, 2023Insider tradeSEC
8-K · Current reportMay 25, 2023Management or board changeSEC
4 · Change in ownershipMay 24, 2023Insider tradeSEC
8-K · Current reportMay 15, 2023Current reportSEC
8-K · Current reportMay 11, 2023ResultsSEC
10-Q · Quarterly reportMay 11, 2023Quarterly reportSEC
8-K · Current reportApr 19, 2023Current reportSEC
DEFA14A · Additional proxy materialMar 31, 2023Meeting noticeSEC
DEF 14A · Proxy statementMar 31, 2023Meeting noticeSEC
10-K · Annual reportMar 23, 2023Annual reportSEC
8-K · Current reportMar 23, 2023ResultsSEC
8-K · Current reportMar 13, 2023Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 9, 2023Big-stake noticeSEC
5/A · Annual statement of ownership, amendedFeb 6, 2023Insider tradeSEC
5 · Annual statement of ownershipFeb 2, 2023Insider tradeSEC
5 · Annual statement of ownershipFeb 2, 2023Insider tradeSEC
5 · Annual statement of ownershipFeb 2, 2023Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 1, 2023Big-stake noticeSEC
3 · Initial statement of ownershipJan 13, 2023Insider tradeSEC
4 · Change in ownershipJan 13, 2023Insider tradeSEC
3 · Initial statement of ownershipJan 13, 2023Insider tradeSEC
8-K · Current reportJan 13, 2023Material contractSEC
8-K · Current reportJan 9, 2023Current reportSEC
8-K · Current reportJan 5, 2023Material contractSEC
8-K · Current reportDec 28, 2022Material contractSEC
4 · Change in ownershipDec 20, 2022Insider tradeSEC
4 · Change in ownershipDec 20, 2022Insider tradeSEC
4 · Change in ownershipDec 20, 2022Insider tradeSEC
4 · Change in ownershipDec 20, 2022Insider tradeSEC
4 · Change in ownershipDec 20, 2022Insider tradeSEC
4 · Change in ownershipDec 20, 2022Insider tradeSEC
4 · Change in ownershipDec 20, 2022Insider tradeSEC
4 · Change in ownershipDec 20, 2022Insider tradeSEC
4 · Change in ownershipDec 20, 2022Insider tradeSEC
4 · Change in ownershipDec 20, 2022Insider tradeSEC
SC 13G · Big-stake noticeDec 20, 2022Big-stake noticeSEC
4 · Change in ownershipDec 12, 2022Insider tradeSEC

This page holds 200 of 610 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Relmada Therapeutics, Inc.’s releases · as of Nov 10, 2026

Common shares
106,694,846
Fully diluted
106,694,846

Fully diluted

LineSharesAs of
Common shares106,694,846Nov 10, 2026

Share count over time

CountShares
Nov 10, 2026106,694,846
Nov 10, 2026106,694,846

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Janus Henderson11.2M10.5%US$42MSep 30, 2026
BlackRock7.58M7.1%US$28.6MSep 30, 2026
Venrock Adviser, LLC7.45M7.0%US$28.1MSep 30, 2026
Spruce Street Capital LP6.91M6.5%US$26.1MSep 30, 2026
Vanguard6.27M5.9%US$23.6MSep 30, 2026
Jones Hill Capital LP5.24M4.9%US$19.7MSep 30, 2026
Adage Capital Partners Gp, L.L.C.4.76M4.5%US$18MSep 30, 2026
Ameriprise3.72M3.5%US$14MSep 30, 2026
Sio Capital Management, LLC3.63M3.4%US$13.7MSep 30, 2026
Squadron Capital Management LLC3.5M3.3%US$13.2MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Millennium3.35M3.1%US$12.6MSep 30, 2026
State Street3.31M3.1%US$12.5MSep 30, 2026
Geode Capital2.36M2.2%US$8.91MSep 30, 2026
Commodore Capital LP2.35M2.2%US$8.86MSep 30, 2026
Franklin Templeton2.25M2.1%US$9.38MSep 30, 2026
Driehaus Capital Management LLC2.13M2.0%US$8.04MSep 30, 2026
Qube Research & Technologies Ltd1.91M1.8%US$7.21MSep 30, 2026
Eventide Asset Management, LLC1.86M1.7%US$7.01MSep 30, 2026
Orbimed Advisors LLC1.67M1.6%US$6.3MSep 30, 2026
Balyasny Asset Management L.P.1.5M1.4%US$5.67MSep 30, 2026
Ikarian Capital, LLC1.45M1.4%US$5.46MSep 30, 2026
Polar Capital Holdings Plc1.34M1.3%US$5.04MSep 30, 2026
Walleye Capital LLC1.02M0.95%US$3.83MSep 30, 2026
Opaleye Management Inc.1M0.94%US$3.77MSep 30, 2026
Corient Private Wealth LP913K0.86%US$3.44MSep 30, 2026
Goldman Sachs881K0.83%US$3.32MSep 30, 2026
Great Point Partners LLC842K0.79%US$3.17MSep 30, 2026
Northern Trust760K0.71%US$2.86MSep 30, 2026
AdvisorShares Investments LLC671K0.63%US$2.53MSep 30, 2026
Marshall Wace, LLP603K0.57%US$2.27MSep 30, 2026
Bank of America581K0.54%US$2.19MSep 30, 2026
ADAR1 Capital Management, LLC552K0.52%US$2.08MSep 30, 2026
Renaissance Technologies503K0.47%US$1.9MSep 30, 2026
Knott David M Jr480K0.45%US$1.81MSep 30, 2026
Citadel442K0.41%US$1.67MSep 30, 2026
Los Angeles Capital Management LLC420K0.39%US$1.59MSep 30, 2026
HighVista Strategies LLC419K0.39%US$1.58MSep 30, 2026
D. E. Shaw & Co., Inc.418K0.39%US$1.58MSep 30, 2026
Birchview Capital, LP408K0.38%US$1.54MSep 30, 2026
UBS406K0.38%US$1.53MSep 30, 2026
Parsons Capital Management Inc404K0.38%US$1.52MSep 30, 2026
Boothbay Fund Management, LLC372K0.35%US$1.4MSep 30, 2026
BNY362K0.34%US$1.36MSep 30, 2026
Diadema Partners LP361K0.34%US$1.36MSep 30, 2026
Wellington336K0.31%US$1.27MSep 30, 2026
Woodline Partners LP328K0.31%US$1.24MSep 30, 2026
Seven Grand Managers, LLC316K0.30%US$1.19MSep 30, 2026
DWS307K0.29%US$1.16MSep 30, 2026
Eversept Partners, LP292K0.27%US$1.1MSep 30, 2026
Schwab283K0.26%US$1.07MSep 30, 2026

This page holds 50 of 131 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund3.17M3.0%US$21.9MJun 30, 2026
iShares Russell 2000 ETF2.09M2.0%US$14.4MJun 30, 2026
Vanguard Extended Market Index Fund1.2M1.1%US$8.34MJun 30, 2026
Fidelity Small Cap Index Fund1.04M0.97%US$5.5MJul 31, 2026
Eventide Healthcare & Life Sciences Fund1.02M0.95%US$7.03MJun 30, 2026
iShares Russell 2000 Growth ETF866K0.81%US$5.99MJun 30, 2026
Franklin Biotechnology Discovery Fund789K0.74%US$4.19MJul 31, 2026
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF655K0.61%US$4.53MJun 30, 2026
AdvisorShares Psychedelics ETF439K0.41%US$3.04MJun 30, 2026
Fidelity Extended Market Index Fund379K0.36%US$2.73MMay 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
iShares Micro-Cap ETF318K0.30%US$2.2MJun 30, 2026
Schwab Small-Cap Index Fund230K0.22%US$1.22MJul 31, 2026
Master Small Cap Index Series177K0.17%US$1.22MJun 30, 2026
iShares Core S&P Total U.S. Stock Market ETF164K0.15%US$1.13MJun 30, 2026
Fidelity Total Market Index Fund144K0.14%US$1.04MMay 31, 2026
Nuveen Small Cap Blend Index Fund125K0.12%US$665KJul 31, 2026
Fidelity Series Total Market Index Fund112K0.10%US$805KMay 31, 2026
EQ/2000 Managed Volatility Portfolio103K0.10%US$710KJun 30, 2026
Fidelity Small Cap Growth Index Fund88,6020.08%US$613KJun 30, 2026
Nuveen Equity Index Fund79,9400.07%US$424KJul 31, 2026
LVIP State Street Small-Cap Index Fund67,9000.06%US$470KJun 30, 2026
U.S. Small Cap Equity Fund62,3370.06%US$331KJul 31, 2026
Fidelity Nasdaq Composite Index Fund62,1000.06%US$448KMay 31, 2026
Schwab Total Stock Market Index Fund53,0810.05%US$282KJul 31, 2026
Goldman Sachs Small Cap Equity Insights Fund50,0190.05%US$266KJul 31, 2026
Small Cap Index Fund47,6240.04%US$330KJun 30, 2026
Virtus Biotech Clinical Trials Etf46,7380.04%US$248KJul 31, 2026
Global X Russell 2000 ETF45,0050.04%US$239KJul 31, 2026
Vanguard Institutional Total Stock Market Index Fund43,5340.04%US$301KJun 30, 2026
Vanguard Balanced Index Fund42,3480.04%US$293KJun 30, 2026
Blackstone Alternative Multi-Strategy Fund41,5280.04%US$287KJun 30, 2026
Invesco RAFI US 1500 Small-Mid ETF38,2080.04%US$203KJul 31, 2026
State Street Small/Mid Cap Equity Index Portfolio32,5000.03%US$225KJun 30, 2026
Goldman Sachs Small Cap Growth Insights Fund31,6400.03%US$168KJul 31, 2026
MetLife Russell 2000 Index Portfolio31,5000.03%US$218KJun 30, 2026
ATM Small Cap Managed Volatility Portfolio29,8420.03%US$207KJun 30, 2026
Fidelity Nasdaq Composite Index ETF29,7820.03%US$215KMay 31, 2026
iShares Russell 3000 ETF29,6060.03%US$205KJun 30, 2026
Small-Cap Index Portfolio27,0960.03%US$188KJun 30, 2026
Direxion Daily Pharmaceutical & Medical Bull 3X Shares23,5360.02%US$125KJul 31, 2026
1290 VT Micro Cap Portfolio21,2180.02%US$147KJun 30, 2026
NVIT Small Cap Index Fund21,0400.02%US$146KJun 30, 2026
Diversified Equity Alpha Master Portfolio19,2230.02%US$133KJun 30, 2026
Small Cap Index Trust19,1460.02%US$132KJun 30, 2026
Profund Vp Pharmaceuticals17,0780.02%US$118KJun 30, 2026
iShares Russell Small/Mid-Cap Index Fund16,5090.02%US$87,663Jul 31, 2026
EQ/Small Company Index Portfolio15,4000.01%US$107KJun 30, 2026
EQ/AB Small Cap Growth Portfolio15,4000.01%US$107KJun 30, 2026
DWS Small Cap Index VIP14,8570.01%US$103KJun 30, 2026
EQ/Morgan Stanley Small Cap Growth Portfolio14,2880.01%US$98,873Jun 30, 2026

This page holds 50 of 87 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Traversa Sergio
Director, Officer: Chief Executive Officer
Buy100,000USD 4.10US$410KSep 10, 2026
Shenouda Maged
Officer: Chief Financial Officer
Buy79,800USD 4.25US$339KSep 10, 2026
Traversa Sergio
Director, Officer: Chief Executive Officer
Buy100,000USD 4.18US$418KSep 9, 2026
Shenouda Maged
Officer: Chief Financial Officer
Buy120,200USD 4.20US$505KSep 9, 2026

Big stakes

StakeStakeSharesDateFiling
Janus Henderson Group PLC10.10%7.44MJan 30, 2026Schedule 13G
BlackRock, Inc.7.00%7.35MJun 30, 2026Schedule 13G
Venrock Healthcare Capital Partners III, L.P.6.20%6.51MJun 2, 2026Schedule 13G
Spruce Street Capital LP5.57%4.09MDec 31, 2025Schedule 13G
Commodore Capital LP5.10%5.51MApr 27, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Charles J. Casamento
Other companies: GT Biopharma, Inc. (Director · Since at least May 1, 2023); Eton Pharmaceuticals, Inc. (Director · Since at least Nov 9, 2018); PaxMedica, Inc. (Director · Oct 1, 2022 – Mar 12, 2024 · Past); GridAI Technologies Corp. (Director · Mar 3, 2017 – Jan 2, 2024 · Past); International Stem Cell Corporation (Director · Mar 31, 2016 – Jun 21, 2018 · Past)
Chairman of the Board · Since at least Oct 20, 2017
Douglas Beck
Other companies: SHF Holdings, Inc. (PAO SVP of Finance Controller · Since at least Sep 24, 2025); ShiftPixy Inc (Chief Financial Officer · Jan 15, 2023 – Jan 15, 2023 · Past); Beyond Air, Inc. (Chief Financial Officer · Nov 1, 2018 – Jun 16, 2021 · Past); iBio, Inc. (Chief Financial Officer · May 3, 2011 – May 3, 2011 · Past); Lev Pharmaceuticals Inc (Chief Financial Officer · Jun 7, 2006 – Jun 7, 2006 · Past)
Chief Financial Officer · Jan 6, 2015 – Feb 23, 2015 · Past
Eric Thomas Schmidt
Other companies: Revolution Medicines, Inc. (Director · Jun 17, 2020 – Jun 8, 2023 · Past); Allogene Therapeutics, Inc. (Chief Financial Officer · Oct 10, 2018 – Mar 22, 2023 · Past)
Director · Dec 19, 2019 – May 25, 2023 · Past
Maged Shenouda
Other companies: GridAI Technologies Corp. (CHIEF FINANCIAL OFFICER, Director · Oct 11, 2016 – Dec 28, 2018 · Past); Protea Biosciences Group (Director · Apr 17, 2015 – Dec 18, 2015 · Past)
Chief Financial Officer · Since at least Nov 12, 2015
Chuck Ence
Other companies: Newage Inc (Chief Financial Officer · Sep 15, 2016 – Sep 15, 2016 · Past)
Chief Accounting and Compliance Officer · Since at least Jul 29, 2019
Lisa Nolan
Other companies: Opus Genetics, Inc. (Chief Business Officer · Jul 6, 2016 – Feb 28, 2019 · Past)
Chief Business Officer · Dec 14, 2015 – Dec 14, 2015 · Past
Sandesh Seth
Other companies: Actinium Pharmaceuticals, Inc. (Delaware) (Chief Executive Officer and Chairman of the Board · Since at least Dec 28, 2012)
Director · Jan 6, 2015 – Dec 15, 2015 · Past
Sergio Traversa
Other companies: Actinium Pharmaceuticals, Inc. (Delaware) (Director · Dec 28, 2012 – Mar 14, 2017 · Past)
Chief Executive Officer · Since at least Jan 6, 2015
Thomas Wessel
Other companies: Decoy Therapeutics Inc. (Chief Medical Officer · Jan 17, 2018 – Jan 17, 2018 · Past)
EVP, Head of R&D · Mar 9, 2020 – Mar 9, 2020 · Past
Bipin DalmiaChief Business Officer · Since Jul 28, 2026
All 19 people
PersonSeat
Cedric O'GormanChief Medical Officer · Jan 6, 2023 – May 23, 2023 · Past
Fabiana FedeliDirector · Since at least Jan 12, 2023
John GlasspoolDirector · Since at least Dec 17, 2021
Jørn Skibsted JakobsenChief Development Officer, Urology & Uro-Oncology · Since Nov 16, 2026
Nabil YazgiDirector · Jan 6, 2015 – Jan 6, 2015 · Past
Ottavio V VitoloCMO · Apr 2, 2018 – Dec 19, 2019 · Past
Paul KellyChief Operating Officer · Since at least Nov 12, 2015
Shreeram AgharkarDirector · Dec 16, 2015 – Dec 31, 2015 · Past
Yair LotanChair of Relmada’s Clinical Advisory Board · Jul 15, 2025 – Nov 4, 2026 · Past

Open People

Log in to ask 6ix AI your own questions about Relmada Therapeutics, Inc.